FindMyKOL
Clinical trialNCT00575029CompletedInterventional

Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate

NCT00575029 is an interventional trial sponsored by University of Arkansas. As of 21 Nov 2026, it is completed. It studies Megestrol in Adrenal Insufficiency. The registry lists an enrollment of 7 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2004 and a primary completion date of 31 Dec 2004.

SponsorUniversity of Arkansas →Enrollment7Adrenal Insufficiency
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00575029
FieldValue
Registry IDNCT00575029
StatusCompleted
Study typeInterventional trial
Lead sponsorUniversity of Arkansas
Enrollment7
Registered sites1
Countries1
ConditionsAdrenal Insufficiency
DrugsMegestrol
Start30 Apr 2004
Primary completion31 Dec 2004
Study completion31 Dec 2004
Last update posted29 Aug 2011

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Megestrol Acetate (MA) is a progesterone-like hormone that has been utilized as a birth control agent, chemotherapeutic drug, and more recently, to induce appetite and weight gain in patients malnourished as a result of radiation therapy, chemotherapy, cystic fibrosis, AIDS, or dementia. The mechanism of MA-stimulated appetite and weight gain is unknown. Although only approved to combat weight loss associated with AIDS and cancer, MA is frequently prescribed for long periods of time to prevent or reverse weight loss in nursing home residents and in elderly patients with serious illnesses in the community. Little data is available to support this practice. Among its many properties, MA acts as a partial glucocorticoid agonist, and long term and short term use of MA may results in adrenal suppression. The rapidity of the onset of MA-induced adrenal suppression and the time course of resumption of normal adrenal function after discontinuation of MA is completely unknown. As a consequence, it is unclear whether MA can be given safely for short periods of time or whether glucocorticoid administration is necessary after abruptly stopping MA treatment. The increased use of MA in the frail elderly, where even partial adrenal insufficiency may pose a substantial risk of adrenal crisis after an illness, requires a clear understanding of these issues. To address these concerns, we will evaluate adrenal function before, during, and after MA administration in healthy volunteers between the ages of 60 and 85 years.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arkansas, United States1 site
  • University of Arkansas for Medical Sciences

    Little Rock

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansas: 1 siteAR1TennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00575029

Each answer restates registry values shown on this page.

What is NCT00575029?

NCT00575029 is an interventional trial sponsored by University of Arkansas. It studies Megestrol in Adrenal Insufficiency.

Who leads NCT00575029?

The registry names donald l bodenner (principal investigator, associate professor) as the overall official.

Where does NCT00575029 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00575029 study?

The registered drug and biological interventions are Megestrol.

When did NCT00575029 end?

The registry lists a primary completion date of 31 Dec 2004 and a study completion date of 31 Dec 2004. The sponsor last updated the record on 29 Aug 2011.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.